Develops immunotherapies for infectious diseases and cancers. Utilizes a proprietary arenavirus platform for therapeutic advancements. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
An average decline of 15% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 99% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $9.7M a year. A small number, but proof the product has real buyers.
There is $37.4M in the vault; even if every debt were paid off, $37.3M would remain.
Over the last 12 months, company executives reported 15 buys and 3 sells. Management buying with its own money is usually read as a good sign.
A loss of $13.8M against $9.7M in annual sales. And on top of that, sales fell from the year before.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 0/10.
Right now the product sells for less than it costs to make; every sale deepens the loss. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.